Alkem Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 07, 2023 at 03:21 am
Share
Alkem Laboratories Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 34,401.7 million compared to INR 30,793.7 million a year ago. Revenue was INR 35,033.6 million compared to INR 31,300.4 million a year ago. Net income was INR 6,205.2 million compared to INR 3,308.4 million a year ago. Basic earnings per share from continuing operations was INR 51.9 compared to INR 27.67 a year ago. Diluted earnings per share from continuing operations was INR 51.9 compared to INR 27.67 a year ago.
For the six months, sales was INR 64,078.9 million compared to INR 56,557.5 million a year ago. Revenue was INR 65,369.2 million compared to INR 57,578.3 million a year ago. Net income was INR 9,072.5 million compared to INR 4,584.8 million a year ago. Basic earnings per share from continuing operations was INR 75.88 compared to INR 38.35 a year ago. Diluted earnings per share from continuing operations was INR 75.88 compared to INR 38.35 a year ago.
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
ALKEM LABORATORIES LIMITED 
